Nanotechnology-based strategies in breast cancer diagnosis and therapy
Peer-Reviewed Publication
Updates every hour. Last Updated: 10-Apr-2026 12:16 ET (10-Apr-2026 16:16 GMT/UTC)
From the Wright brothers’ first flight to the speedy development of COVID-19 vaccines, collaboration has been key to innovation. Paradoxically, even competitors can benefit from collaboration — when they hold different pieces of the same puzzle.
But these companies must strike a delicate balance, according to new research from the McCombs School of Business at The University of Texas at Austin. Ramkumar Ranganathan, associate professor of management, offers some principles for managing the balance between competition and collaboration — particularly when it involves sharing information. "Firms need to pay attention to these longer-term issues,” he says. “It’s very easy to look at the short term and think, ‘This alliance partner is giving me X amount of money to co-develop this technology. So, what if I don’t let this person talk to this other person for a few months? That shouldn’t matter, right?’ But it does matter.”
A research team led by Sir Run-Run Shaw Hospital, Zhejiang University School of Medicine, has published a comprehensive review in ExRNA that sorts out the diverse roles of extracellular vesicle-associated RNAs (EV-RNAs) in the development and progression of inflammatory bowel disease (IBD). By integrating the latest findings from multi-omics studies and animal experiments, the review points out that EV-RNAs can serve as non-invasive biomarkers for early IBD detection and disease monitoring, and also hold great potential as targets for next-generation targeted therapies. This work provides a solid theoretical basis for advancing personalized precision treatment for the millions of IBD patients worldwide suffering from this chronic recurrent gastrointestinal disorder.
As traditional power plants are replaced by intermittent sources like solar and wind, maintaining grid stability has become a complex engineering challenge. Hussain Khan’s doctoral dissertation at the University of Vaasa, Finland, introduces advanced AI-based control strategies that ensure local grids remain reliable and resilient.
The rapid evolution of CRISPR/Cas genome editing has redefined the possibilities of cellular and gene therapy, enabling precise correction, disruption, and regulation of disease-associated genes. Yet, as genome editing technologies transition from laboratory innovation to clinical application, ensuring robust non-clinical safety assessment has become a critical priority.